Lenalidomide (CC-5013)是thalidomide的4-氨基-谷氨酰类似物，具有更强的效力，且不具有thalidomide相关的镇静和神经病变等神经系统副作用。
Cas No.:191732-72-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lenalidomide (CC-5013) is a 4-amino-glutamyl analog of thalidomide, with greater potency and without the sedative and neuropathic side effects associated with thalidomide. Lenalidomide is an immunomodulator, affecting both the cellular and humoral arms of the immune system, and has demonstrated activity in clinical trials for cancer, including anti-angiogenic, anti-proliferative, and pro-erythropoietic activities. Lenalidomide acts as a molecular glue that binds to the CRBN-CRL4 E3 ubiquitin ligase complex, promoting ubiquitination of Ikaros family zinc finger 1 (IKZF1) and IKZF3 and thereby inhibiting proliferation of multiple myeloma cells. Lenalidomide is approved in the United States for a subset of Myelodysplastic Syndromes (MDS) patients and for treatment of patients with multiple myeloma when used in combination with dexamethasone[1][2].
In vitro, Lenalidomide (0.1-10μM; 72h) dose-dependently inhibited proliferation of CFSE-labeled OPM1 cells, regardless of co-culture with HS-5 BMSCs, significantly reduced the percentage of side population (SP) cells, and increased the proportions of CD138−/low+ and CFSE+/7-AAD+ cells[3]. Lenalidomide (10μM; 6h) inhibited the suppression of IL-2–induced NK cell cytotoxicity and IFN-γ secretion mediated by IL-6 and TGF-β1 in neuroblastoma/monocyte-conditioned media[4].
In vivo, in female NOD/SCID mice injected with CHLA-255-Fluc neuroblastoma cells and PBMCs, treatment with Lenalidomide (50mg/kg/d; 9+5d; i.p.) in combination with ch14.18 improved survival[4]. Lenalidomide (50mg/kg/d; 21d; i.p.) inhibited tumor growth and spread in xenograft mouse models of Mantle cell lymphoma (MCL)[5].
References:
[1] Krönke J, Hurst SN, Ebert BL. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014;3(7):e941742.
[2] Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
[3] Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117(17):4409-4419.
[4] Xu Y, Sun J, Sheard MA, et al. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother. 2013;62(10):1637-1648.
[5] Agliano, Alice et al. “Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 17,19 (2011): 6163-73.
Lenalidomide (CC-5013)是thalidomide的4-氨基-谷氨酰类似物，具有更强的效力，且不具有thalidomide相关的镇静和神经病变等神经系统副作用。Lenalidomide是一种免疫调节剂，影响免疫系统的细胞和体液分支，并在癌症的临床试验中显示出活性，包括抗血管生成、抗增殖和促红细胞生成活性。Lenalidomide作为一种分子胶，结合于CRBN-CRL4 E3泛素连接酶复合体，促进Ikaros锌指家族蛋白1（IKZF1）和IKZF3的泛素化，从而抑制多发性骨髓瘤细胞的增殖。Lenalidomide已在美国获批用于部分骨髓增生异常综合征（MDS）患者以及与地塞米松联合使用治疗多发性骨髓瘤患者[1][2]。
体外实验中，Lenalidomide（0.1–10μM；72h）以剂量依赖方式抑制了CFSE标记的OPM1细胞的增殖（无论是否与HS-5 BMSCs共培养），显著降低了侧群（SP）细胞的比例，并增加了CD138−/low+细胞和CFSE+/7-AAD+细胞的比例[3]。Lenalidomide（10μM；6h）可抑制神经母细胞瘤/单核细胞条件培养基中IL-6和TGF-β1对IL-2诱导的NK细胞细胞毒性和IFN-γ分泌的抑制作用[4]。
体内实验中，在注射了CHLA-255-Fluc神经母细胞瘤细胞和PBMC的雌性NOD/SCID小鼠中，Lenalidomide（50mg/kg/天；9+5天；腹腔注射）联合ch14.18治疗可提高小鼠生存率[4]。Lenalidomide（50mg/kg/天；21天；腹腔注射）抑制了套细胞淋巴瘤（MCL）异种移植小鼠模型中的肿瘤生长和扩散[5]。
| Cell experiment [1]: | |
Cell lines | CFSE-labeled OPM1 cells and OPM1 cells co-cultured with HS-5 BMSCs |
Preparation Method | Lenalidomide was dissolved in DMSO. |
Reaction Conditions | 0.1-10μM; 72h |
Applications | Lenalidomide significantly decreased the percentage of side population (SP) cells in a dose-dependent manner at 72 hours. Lenalidomide treatment inhibited cell proliferation of OPM1 cells either alone or with BMSCs. The percentage of CD138−/low+ population was increased after addition of Lenalidomide to OPM1 cells, alone or cocultured with BMSCs. BMSCs and lenalidomide slightly increased the proportion of CFSE+/7-AAD+ cells at 72 hours. |
| Animal experiment [2]: | |
Animal models | Female NOD/SCID mice |
Preparation Method | CHLA-255-Fluc neuroblastoma cells and PBMC (0.25×106; CD3+ 75.3%; CD3-CD56+CD16+ 2.7%) or NK cell depleted PBMC (PBMC-NK) (0.25×106; CD3+ 82.6%; CD3-CD56+CD16+ 0.02%) were co-injected into NOD/SCID mice near the right and left shoulders in 25% (v/v) BD Matrigel®Matrix Growth Factor Reduced on day 0. Treatment began on day 1 (after imaging and randomization) with Lenalidomide alone (50mg/kg/d intraperitoneal days 1-9 and 12-16), ch14.18 alone (15μg/mouse intravenous days 3, 5, 8, and 12), or the combination of lenalidomide and ch14.18 using the same doses and schedules. |
Dosage form | 50mg/kg/d; 9+5d; i.p. |
Applications | After 14 days of treatment, Lenalidomide combined with ch14.18 most effectively suppressed tumor cell growth (AUC) compared to untreated, Lenalidomide alone, or ch14.18 alone-treated mice. Survival time was also longer for the Lenalidomide plus ch14.18-treated group than for untreated, Lenalidomide-treated or ch14.18-treated groups. When mice receiving NK-depleted PBMC were treated with Lenalidomide plus ch14.18, they had greater tumor growth and poorer survival than the PBMC group. Tumor growth was no different for these two groups treated with Lenalidomide or ch14.18 alone, and survival was no different for Lenalidomide but was marginally poorer for the NK-depleted group and ch14.18 alone-treated group. Together, these data indicate that Lenalidomide enhances survival of mice treated with ch14.18 and that this in vivo effect involves NK cells. |
References: | |
| Cas No. | 191732-72-6 | SDF | |
| 别名 | 来那度胺; CC-5013 | ||
| 化学名 | 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione | ||
| Canonical SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N | ||
| 分子式 | C13H13N3O3 | 分子量 | 259.3 |
| 溶解度 | ≥ 100.8 mg/mL in DMSO | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8565 mL | 19.2827 mL | 38.5654 mL |
| 5 mM | 771.3 μL | 3.8565 mL | 7.7131 mL |
| 10 mM | 385.7 μL | 1.9283 mL | 3.8565 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet